Modeling cancer metabolism on a genome scale

Molecular Systems Biology

Volumn 11, Issue 6, 2015, Pages

  Yizhak, Keren ^a   Chaneton, Barbara ^b   Gottlieb, Eyal ^b   Ruppin, Eytan ^a,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c Bldg 142   (United States)

Author keywords

Cancer metabolism; Genome scale simulations; Metabolic modeling

Indexed keywords

BIOLOGICAL MODEL; GENETICS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; SYSTEMS BIOLOGY;

HUMANS; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; NEOPLASMS; SYSTEMS BIOLOGY;

EID: 84934288620     PISSN: None     EISSN: 17444292     Source Type: Journal    
DOI: 10.15252/msb.20145307     Document Type: Review

References (160)

1. Agren R, Bordel S, Mardinoglu A, Pornputtapong N, Nookaew I, Nielsen J, (2012) Reconstruction of genome-scale active metabolic networks for 69 human cell types and 16 cancer types using INIT. PLoS Comput Biol 8: e1002518
2. Agren R, Mardinoglu A, Asplund A, Kampf C, Uhlen M, Nielsen J, (2014) Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling. Mol Syst Biol 10: 721
3. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale A-L, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjord JE, Foekens JA, Greaves M, et al, (2013) Signatures of mutational processes in human cancer. Nature 500: 415-421
4. Alo PL, Visca P, Marci A, Mangoni A, Botti C, Di Tondo U, (1996) Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77: 474-482
5. Anesiadis N, Cluett WR, Mahadevan R, (2008) Dynamic metabolic engineering for increasing bioprocess productivity. Metab Eng 10: 255-266
6. Armitage EG, Barbas C, (2014) Metabolomics in cancer biomarker discovery: current trends and future perspectives. J Pharm Biomed Anal 87: 1-11
7. Asgari Y, Salehzadeh-Yazdi A, Schreiber F, Masoudi-Nejad A, (2013) Controllability in cancer metabolic networks according to drug targets as driver nodes. PLoS ONE 8: e79397
8. Becker SA, Palsson BO, (2008) Context-specific metabolic networks are consistent with experiments. PLoS Comput Biol 4: e1000082
9. Bjarnadottir O, Romero Q, Bendahl P-O, Jirström K, Rydén L, Loman N, Uhlén M, Johannesson H, Rose C, Grabau D, Borgquist S, (2013) Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat 138: 499-508
10. Bordbar A, Feist A, Usaite-Black R, Woodcock J, Palsson B, Famili I, (2011) A multi-tissue type genome-scale metabolic network for analysis of whole-body systems physiology. BMC Syst Biol 5: 180
11. Bordbar A, Palsson BO, (2012) Using the reconstructed genome-scale human metabolic network to study physiology and pathology. J Intern Med 271: 131-141
12. Bordbar A, Monk JM, King ZA, Palsson BO, (2014) Constraint-based models predict metabolic and associated cellular functions. Nat Rev Genet 15: 107-120
13. Bordel S, Agren R, Nielsen J, (2010) Sampling the solution space in genome-scale metabolic networks reveals transcriptional regulation in key enzymes. PLoS Comput Biol 6: e1000859
14. Bro C, Regenberg B, Förster J, Nielsen J, (2006) In silico aided metabolic engineering of Saccharomyces cerevisiae for improved bioethanol production. Metab Eng 8: 102-111
15. Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV, (2005) RNA interference-mediated silencing of the Acetyl-CoA-Carboxylase-α gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 65: 6719-6725
16. Bunnage ME, (2011) Getting pharmaceutical R&D back on target. Nat Chem Biol 7: 335-339
17. Cairns RA, Harris IS, Mak TW, (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11: 85-95
18. Calin GA, Croce CM, (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866
19. Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EW, Banh A, Reynolds GE, Chi J-T, Wu J, Solow-Cordero DE, Bonnet M, Flanagan JU, Bouley DM, Graves EE, Denny WA, Hay MP, Giaccia AJ, (2011) Targeting GLUT1 and the warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med 3: 94ra70
20. Chang RL, Andrews K, Kim D, Li Z, Godzik A, Palsson BO, (2013) Structural systems biology evaluation of metabolic thermotolerance in Escherichia Coli. Science 340: 1220-1223
21. Cheong H, Lu C, Lindsten T, Thompson CB, (2012) Therapeutic targets in cancer cell metabolism and autophagy. Nat Biotechnol 30: 671-678
22. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC, (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233
23. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES, Getz G, (2013) Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotech 31: 213-219
24. Colijn C, Brandes A, Zucker J, Lun DS, Weiner B, Farhat MR, Cheng T-Y, Moody DB, Murray M, Galagan JE, (2009) Interpreting expression data with metabolic flux models: predicting mycobacterium tuberculosis mycolic acid production. PLoS Comput Biol 5: e1000489
25. Consortium TEP, (2012) An integrated encyclopedia of DNA elements in the human genome. Nature 489: 57-74
26. Cotten C, Reed J, (2013) Mechanistic analysis of multi-omics datasets to generate kinetic parameters for constraint-based metabolic models. BMC Bioinformatics 14: 32
27. Covert MW, Knight EM, Reed JL, Herrgard MJ, Palsson BO, (2004) Integrating high-throughput and computational data elucidates bacterial networks. Nature 429: 92-96
28. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM, (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739-744
29. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB, (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20
30. Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T, Szlosarek PW, (2010) Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer 126: 2762-2772
31. Dolfi S, Chan L, Qiu J, Tedeschi P, Bertino J, Hirshfield K, Oltvai Z, Vazquez A, (2013) The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. Cancer Metab 1: 20
32. Duarte NC, Herrgard MJ, Palsson BO, (2004) Reconstruction and validation of Saccharomyces cerevisiae iND750, a fully compartmentalized genome-scale metabolic model. Genome Res 14: 1298-1309
33. Duarte N, Becker S, Jamshidi N, Thiele I, Mo M, Vo T, Srivas R, Palsson B, (2007) Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci USA 104: 1777-1782
34. Dunn WB, Bailey NJC, Johnson HE, (2005) Measuring the metabolome: current analytical technologies. Analyst 130: 606-625
35. Facchetti G, Zampieri M, Altafini C, (2012) Predicting and characterizing selective multiple drug treatments for metabolic diseases and cancer. BMC Syst Biol 6: 115
36. Fan J, Ye J, Kamphorst JJ, Shlomi T, Thompson CB, Rabinowitz JD, (2014) Quantitative flux analysis reveals folate-dependent NADPH production. Nature 510: 298-302
37. Feizi A, Bordel S, (2013) Metabolic and protein interaction sub-networks controlling the proliferation rate of cancer cells and their impact on patient survival. Sci Rep 3: 3041
38. Feun L, Savaraj N, (2006) Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin Investig Drugs 15: 815-822
39. Florian CL, Preece NE, Bhakoo KK, Williams SR, Noble M, (1995) Characteristic metabolic profiles revealed by 1H NMR spectroscopy for three types of human brain and nervous system tumours. NMR Biomed 8: 253-264
40. Folger O, Jerby L, Frezza C, Gottlieb E, Ruppin E, Shlomi T, (2011) Predicting selective drug targets in cancer through metabolic networks. Mol Syst Biol 7: 501
41. Freilich S, Zarecki R, Eilam O, Segal ES, Henry CS, Kupiec M, Gophna U, Sharan R, Ruppin E, (2011) Competitive and cooperative metabolic interactions in bacterial communities. Nat Commun 2: 589
42. Frezza C, Pollard P, Gottlieb E, (2011a) Inborn and acquired metabolic defects in cancer. J Mol Med 89: 213-220
43. Frezza C, Zheng L, Folger O, Rajagopalan KN, MacKenzie ED, Jerby L, Micaroni M, Chaneton B, Adam J, Hedley A, Kalna G, Tomlinson IPM, Pollard PJ, Watson DG, Deberardinis RJ, Shlomi T, Ruppin E, Gottlieb E, (2011b) Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 477: 225-228
44. Fumiã HF, Martins ML, (2013) Boolean network model for cancer pathways: predicting carcinogenesis and targeted therapy outcomes. PLoS ONE 8: e69008
45. Gatto F, Nookaew I, Nielsen J, (2014) Chromosome 3p loss of heterozygosity is associated with a unique metabolic network in clear cell renal carcinoma. Proc Natl Acad Sci USA 111: E866-E875
46. Gautier EL, Westerterp M, Bhagwat N, Cremers S, Shih A, Abdel-Wahab O, Lütjohann D, Randolph GJ, Levine RL, Tall AR, Yvan-Charvet L, (2013) HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. J Exp Med 210: 339-353
47. Glunde K, Raman V, Mori N, Bhujwalla ZM, (2005) RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res 65: 11034-11043
48. Goldstein I, Yizhak K, Madar S, Goldfinger N, Ruppin E, Rotter V, (2013) p53 promotes the expression of gluconeogenesis-related genes and enhances hepatic glucose production. Cancer Metab 1: 9
49. Gottesman MM, (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627
50. Griffiths WJ, Koal T, Wang Y, Kohl M, Enot DP, Deigner H-P, (2010) Targeted metabolomics for biomarker discovery. Angew Chem Int Ed 49: 5426-5445
51. Guertin DA, Sabatini DM, (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9-22
52. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674
53. Haskell CM, Canellos GP, Leventhal BG, Carbone PP, Block JB, Serpick AA, Selawry OS, (1969) L-Asparaginase. New Engl J Med 281: 1028-1034
54. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB, (2005) ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8: 311-321
55. Helmlinger G, Yuan F, Dellian M, Jain RK, (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3: 177-182
56. Herrgard MJ, Lee BS, Portnoy V, Palsson BO, (2006) Integrated analysis of regulatory and metabolic networks reveals novel regulatory mechanisms in Saccharomyces cerevisiae. Genome Res 16: 627-635
57. Herrgard MJ, Swainston N, Dobson P, Dunn WB, Arga KY, Arvas M, Bluthgen N, Borger S, Costenoble R, Heinemann M, (2008) A consensus yeast metabolic network reconstruction obtained from a community approach to systems biology. Nat Biotech 26: 1155-1160
58. Higareda-Almaraz J, Enriquez-Gasca M, Hernandez-Ortiz M, Resendis-Antonio O, Encarnacion-Guevara S, (2011) Proteomic patterns of cervical cancer cell lines, a network perspective. BMC Syst Biol 5: 96
59. Hopkins AL, Groom CR, (2002) The druggable genome. Nat Rev Drug Discov 1: 727-730
60. Horvath S, Zhang B, Carlson M, Lu KV, Zhu S, Felciano RM, Laurance MF, Zhao W, Qi S, Chen Z, Lee Y, Scheck AC, Liau LM, Wu H, Geschwind DH, Febbo PG, Kornblum HI, Cloughesy TF, Nelson SF, Mischel PS, (2006) Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci USA 103: 17402-17407
61. Jerby L, Shlomi T, Ruppin E, (2010) Computational reconstruction of tissue-specific metabolic models: application to human liver metabolism. Mol Syst Biol 6: 401
62. Jerby L, Ruppin E, (2012) Predicting drug targets and biomarkers of cancer via genome-scale metabolic modeling. Clin Cancer Res 18: 5572-5584
63. Jerby L, Wolf L, Denkert C, Stein GY, Hilvo M, Oresic M, Geiger T, Ruppin E, (2012) Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer. Cancer Res 72: 5712-5720
64. Karr JR, Sanghvi Jayodita C, Macklin Derek N, Gutschow Miriam V, Jacobs Jared M, Bolival B Jr, Assad-Garcia N, Glass John I, Covert Markus W, (2012) A whole-cell computational model predicts phenotype from genotype. Cell 150: 389-401
65. Kim P-J, Lee D-Y, Kim TY, Lee KH, Jeong H, Lee SY, Park S, (2007) Metabolite essentiality elucidates robustness of Escherichia coli metabolism. Proc Natl Acad Sci USA 104: 13638-13642
66. Kim HU, Kim TY, Lee SY, (2010) Genome-scale metabolic network analysis and drug targeting of multi-drug resistant pathogen Acinetobacter baumannii AYE. Mol BioSyst 6: 339-348
67. Kiuru M, Lehtonen R, Arola J, Salovaara R, Järvinen H, Aittomäki K, Sjöberg J, Visakorpi T, Knuutila S, Isola J, Delahunt B, Herva R, Launonen V, Karhu A, Aaltonen LA, (2002) Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res 62: 4554-4557
68. Kotze H, Armitage E, Sharkey K, Allwood J, Dunn W, Williams K, Goodacre R, (2013) A novel untargeted metabolomics correlation-based network analysis incorporating human metabolic reconstructions. BMC Syst Biol 7: 107
69. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW, (2004) Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64: 2070-2075
70. Kuepfer L, (2010) Towards whole-body systems physiology. Mol Syst Biol 6: 409
71. Laird AK, (1964) Dynamics of tumor growth. Br J Cancer 18: 490-502
72. Lane AN, Fan TWM, Higashi RM, Tan J, Bousamra M, Miller DM, (2009) Prospects for clinical cancer metabolomics using stable isotope tracers. Exp Mol Pathol 86: 165-173
73. Lankelma J, Fernández Luque R, Dekker H, van den Berg J, Kooi B, (2013) A new mathematical pharmacodynamic model of clonogenic cancer cell death by doxorubicin. J Pharmacokinet Pharmacodyn 40: 513-525
74. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, Drier Y, Zou L, Ramos AH, Pugh TJ, Stransky N, Helman E, Kim J, et al, (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499: 214-218
75. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G, (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505: 495-501
76. Lee D, Smallbone K, Dunn W, Murabito E, Winder C, Kell D, Mendes P, Swainston N, (2012) Improving metabolic flux predictions using absolute gene expression data. BMC Syst Biol 6: 73
77. Lewis NE, Abdel-Haleem AM, (2013) The evolution of genome-scale models of cancer metabolism. Front Physiol 4: 237
78. Li MC, Hertz R, Spencer DB, (1956) Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Exp Biol Med 93: 361-366
79. Li L, Zhou X, Ching W-K, Wang P, (2010) Predicting enzyme targets for cancer drugs by profiling human Metabolic reactions in NCI-60 cell lines. BMC Bioinformatics 11: 501
80. Lobo C, Ruiz-Bellido MA, Aledo JC, Márquez J, Núñez De Castro I, Alonso FJ, (2000) Inhibition of glutaminase expression by antisense mRNA decreases growth and tumourigenicity of tumour cells. Biochem J 348 (Pt 2): 257-261
81. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, Heffron G, Metallo CM, Muranen T, Sharfi H, Sasaki AT, Anastasiou D, Mullarky E, Vokes NI, Sasaki M, Beroukhim R, Stephanopoulos G, Ligon AH, Meyerson M, Richardson AL, et al, (2011) Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 43: 869-874
82. Ma H, Sorokin A, Mazein A, Selkov A, Selkov E, Demin O, Goryanin I, (2007) The Edinburgh human metabolic network reconstruction and its functional analysis. Mol Syst Biol 3: 135
83. Machado D, Herrgård M, (2014) Systematic evaluation of methods for integration of transcriptomic data into constraint-based models of metabolism. PLoS Comput Biol 10: e1003580
84. Mardinoglu A, Nielsen J, (2012) Systems medicine and metabolic modelling. J Intern Med 271: 142-154
85. Mardinoglu A, Agren R, Kampf C, Asplund A, Nookaew I, Jacobson P, Walley AJ, Froguel P, Carlsson LM, Uhlen M, Nielsen J, (2013a) Integration of clinical data with a genome-scale metabolic model of the human adipocyte. Mol Syst Biol 9: 649
86. Mardinoglu A, Gatto F, Nielsen J, (2013b) Genome-scale modeling of human metabolism-a systems biology approach. Biotechnol J 8: 985-996
87. Mardinoglu A, Agren R, Kampf C, Asplund A, Uhlen M, Nielsen J, (2014) Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. Nat Commun 5: 3083
88. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini VJ, Abbott RM, Vickery TL, Reed JS, Robinson JS, Wylie T, Smith SM, Carmichael L, et al, (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361: 1058-1066
89. McCarthy N, (2013) Therapeutics: targeting an oncometabolite. Nat Rev Cancer 13: 383-383
90. Menendez JA, Vellon L, Lupu R, (2006) The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin) in chemoresistant ovarian cancer cells. Int J Gynecol Cancer 16: 219-221
91. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, Jewell CM, Johnson ZR, Irvine DJ, Guarente L, Kelleher JK, Vander Heiden MG, Iliopoulos O, Stephanopoulos G, (2012) Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481: 380-384
92. Mo M, Palsson B, Herrgard M, (2009) Connecting extracellular metabolomic measurements to intracellular flux states in yeast. BMC Syst Biol 3: 37
93. Monk J, Nogales J, Palsson BO, (2014) Optimizing genome-scale network reconstructions. Nat Biotech 32: 447-452
94. Morandi A, Chiarugi P, (2014) Metabolic implication of tumor:stroma crosstalk in breast cancer. J Mol Med 92: 117-126
95. Mullen AR, Wheaton WW, Jin ES, Chen P-H, Sullivan LB, Cheng T, Yang Y, Linehan WM, Chandel NS, DeBerardinis RJ, (2012) Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481: 385-388
96. Nam H, Lewis NE, Lerman JA, Lee D-H, Chang RL, Kim D, Palsson BO, (2012) Network context and selection in the evolution to enzyme specificity. Science 337: 1101-1104
97. Nam H, Campodonico M, Bordbar A, Hyduke DR, Kim S, Zielinski DC, Palsson BO, (2014) A systems approach to predict oncometabolites via context-specific genome-scale metabolic networks. PLoS Comput Biol 10: e1003837
98. Niklas J, Schneider K, Heinzle E, (2010) Metabolic flux analysis in eukaryotes. Curr Opin Biotechnol 21: 63-69
99. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng S-W, Cravatt BF, (2010) Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140: 49-61
100. Notebaart RA, Szappanos B, Kintses B, Pál F, Györkei Á, Bogos B, Lázár V, Spohn R, Csörgo′ B, Wagner A, Ruppin E, Pál C, Papp B, (2014) Network-level architecture and the evolutionary potential of underground metabolism. Proc Natl Acad Sci USA 111: 11762-11767
101. Oberhardt MA, Palsson BO, Papin JA, (2009) Applications of genome-scale metabolic reconstructions. Mol Syst Biol 5: 320
102. Oberhardt MA, Yizhak K, Ruppin E, (2013) Metabolically re-modeling the drug pipeline. Curr Opin Pharmacol 13: 778-785
103. Oh YK, Palsson BO, Park SM, Schilling CH, Mahadevan R, (2007) Genome-scale reconstruction of metabolic network in bacillus subtilis based on high-throughput phenotyping and gene essentiality data. J Biol Chem 282: 28791-28799
104. de Oliveira Dal'Molin CG, Nielsen LK, (2013) Plant genome-scale metabolic reconstruction and modelling. Curr Opin Biotechnol 24: 271-277
105. Orth JD, Thiele I, Palsson BO, (2010) What is flux balance analysis? Nat Biotech 28: 245-248
106. Orth JD, Conrad TM, Na J, Lerman JA, Nam H, Feist AM, Palsson BØ, (2011) A comprehensive genome-scale reconstruction of Escherichia coli metabolism-2011. Mol Syst Biol 7: 535
107. Pál C, Papp B, Lercher MJ, Csermely P, Oliver SG, Hurst LD, (2006) Chance and necessity in the evolution of minimal metabolic networks. Nature 440: 667-670
108. Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu I-M, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA, Hartigan J, et al, (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812
109. Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, Goekbuget N, Schrappe M, Pui CH, (2011) L-Asparaginase treatment in acute lymphoblastic leukemia. Cancer 117: 238-249
110. Pollari S, Käkönen S-M, Edgren H, Wolf M, Kohonen P, Sara H, Guise T, Nees M, Kallioniemi O, (2011) Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. Breast Cancer Res Treat 125: 421-430
111. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, Sethumadhavan S, Woo HK, Jang HG, Jha AK, Chen WW, Barrett FG, Stransky N, Tsun ZY, Cowley GS, Barretina J, Kalaany NY, Hsu PP, Ottina K, Chan AM, et al, (2011) Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476: 346-350
112. Resendis-Antonio O, Checa A, Encarnaciõn S, (2010) Modeling core metabolism in cancer cells: surveying the topology underlying the warburg effect. PLoS ONE 5: e12383
113. Resendis-Antonio O, González-Torres C, Jaime-Muñoz G, Hernandez-Patiño CE, Salgado-Muñoz CF, (2014) Modeling metabolism: a window toward a comprehensive interpretation of networks in cancer. Semin Cancer Biol 30: 79-87
114. Ritchie S, Ahiahonu P, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan A, Hossain M, Su-Myat K, Wood P, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, et al, (2010) Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med 8: 13
115. Samid D, Shack S, Myers CE, (1993) Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest 91: 2288-2295
116. Schmidt BJ, Ebrahim A, Metz TO, Adkins JN, Palsson BØ, Hyduke DR, (2013) GIM3E: condition-specific models of cellular metabolism developed from metabolomics and expression data. Bioinformatics 29: 2900-2908
117. Segre D, Vitkup D, Church GM, (2002) Analysis of optimality in natural and perturbed metabolic networks. Proc Natl Acad Sci USA 99: 15112-15117
118. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, Tsukamoto T, Rojas CJ, Slusher BS, Rabinowitz JD, Dang CV, Riggins GJ, (2010) Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 70: 8981-8987
119. Semenza GL, (2010) HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20: 51-56
120. Shaw RJ, Cantley LC, (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430
121. Shen Y, Liu J, Estiu G, Isin B, Ahn Y-Y, Lee D-S, Barabási A-L, Kapatral V, Wiest O, Oltvai ZN, (2010) Blueprint for antimicrobial hit discovery targeting metabolic networks. Proc Natl Acad Sci USA 107: 1082-1087
122. Shlomi T, Berkman O, Ruppin E, (2005) Regulatory on/off minimization of metabolic flux changes after genetic perturbations. Proc Natl Acad Sci USA 102: 7695-7700
123. Shlomi T, Eisenberg Y, Sharan R, Ruppin E, (2007) A genome-scale computational study of the interplay between transcriptional regulation and metabolism. Mol Syst Biol 3: 101
124. Shlomi T, Benyamini T, Gottlieb E, Sharan R, Ruppin E, (2011) Genome-scale metabolic modeling elucidates the role of proliferative adaptation in causing the warburg effect. PLoS Comput Biol 7: e1002018
125. Simon R, Roychowdhury S, (2013) Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov 12: 358-369
126. Soliman LC, Hui Y, Hewavitharana AK, Chen DDY, (2012) Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. J Chromatogr A 1267: 162-169
127. Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K, Oster ZH, Sacker DF, Shiue CY, Turner H, Wan C-N, Wolf AP, Zabinski SV, (1980) A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 21: 670-675
128. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, Perera RM, Ferrone CR, Mullarky E, Shyh-Chang N, Kang Y, Fleming JB, Bardeesy N, Asara JM, Haigis MC, DePinho RA, Cantley LC, Kimmelman AC, (2013) Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496: 101-105
129. Srihari S, Raman V, Wai Leong H, Ragan MA, (2014) Evolution and controllability of cancer networks: a boolean perspective. IEEE/ACM Trans Comput Biol Bioinform 11: 83-94
130. Tate AR, Griffiths JR, Martínez-Pérez I, Moreno À, Barba I, Cabañas ME, Watson D, Alonso J, Bartumeus F, Isamat F, Ferrer I, Vila F, Ferrer E, Capdevila A, Arús C, (1998) Towards a method for automated classification of 1H MRS spectra from brain tumours. NMR Biomed 11: 177-191
131. Thiele I, Palsson BO, (2010) A protocol for generating a high-quality genome-scale metabolic reconstruction. Nat Protoc 5: 93-121
132. Thiele I, Swainston N, Fleming RMT, Hoppe A, Sahoo S, Aurich MK, Haraldsdottir H, Mo ML, Rolfsson O, Stobbe MD, Thorleifsson SG, Agren R, Bolling C, Bordel S, Chavali AK, Dobson P, Dunn WB, Endler L, Hala D, Hucka M, et al, (2013) A community-driven global reconstruction of human metabolism. Nat Biotechnol 31: 419-425
133. Tomlinson I, Alam N, Rowan A, (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30: 406-410
134. Urayama S, Zou W, Brooks K, Tolstikov V, (2010) Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun Mass Spectrom 24: 613-620
135. Vander Heiden MG, Cantley LC, Thompson CB, (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033
136. Vazquez A, Liu J, Zhou Y, Oltvai ZN, (2010) Catabolic efficiency of aerobic glycolysis: the warburg effect revisited. BMC Syst Biol 4: 58
137. Vazquez A, Oltvai ZN, (2011) Molecular crowding defines a common origin for the warburg effect in proliferating cells and the lactate threshold in muscle physiology. PLoS ONE 6: e19538
138. Vazquez-Martin A, Ropero S, Brunet J, Colomer R, Menendez JA, (2007) Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells. Oncol Rep 18: 973-980
139. Wagner A, Zarecki R, Reshef L, Gochev C, Sorek R, Gophna U, Ruppin E, (2013) Computational evaluation of cellular metabolic costs successfully predicts genes whose expression is deleterious. Proc Natl Acad Sci USA 110: 19166-19171
140. Wang R-S, Saadatpour A, Albert R, (2012a) Boolean modeling in systems biology: an overview of methodology and applications. Phys Biol 9: 055001
141. Wang Y, Eddy J, Price N, (2012b) Reconstruction of genome-scale metabolic models for 126 human tissues using mCADRE. BMC Syst Biol 6: 153
142. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, Straley K, Kernytsky A, Liu W, Gliser C, Yang H, Gross S, Artin E, Saada V, Mylonas E, Quivoron C, Popovici-Muller J, Saunders JO, Salituro FG, Yan S, et al, (2013) Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340: 622-626
143. Warburg O, (1956) On the origin of cancer cells. Science 123: 309-314
144. Ward PS, Thompson CB, (2012) Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21: 297-308
145. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB, Thompson CB, (2008) Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 105: 18782-18787
146. Wise DR, Thompson CB, (2010) Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 35: 427-433
147. Wu G, Stein L, (2012) A network module-based method for identifying cancer prognostic signatures. Genome Biol 13: R112
148. Wu M, Chan C, (2014) Prediction of therapeutic microRNA based on the human metabolic network. Bioinformatics doi: 10.1093/bioinformatics/btt751
149. Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot Chad V, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, Liu J, Shmulevich I, Sood Anil K, Chen K, Zhang W, (2013a) Integrated analyses identify a master MicroRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 23: 186-199
150. Yang M, Soga T, Pollard PJ, (2013b) Oncometabolites: linking altered metabolism with cancer. J Clin Invest 123: 3652-3658
151. Yang C, Ko B, Hensley Christopher T, Jiang L, Wasti Ajla T, Kim J, Sudderth J, Calvaruso Maria A, Lumata L, Mitsche M, Rutter J, Merritt Matthew E, DeBerardinis Ralph J, (2014) Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol Cell 56: 414-424
152. Ye J, Mancuso A, Tong X, Ward PS, Fan J, Rabinowitz JD, Thompson CB, (2012) Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc Natl Acad Sci USA 109: 6904-6909
153. Yen KE, Bittinger MA, Su SM, Fantin VR, (2010) Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene 29: 6409-6417
154. Yizhak K, Benyamini T, Liebermeister W, Ruppin E, Shlomi T, (2010) Integrating quantitative proteomics and metabolomics with a genome-scale metabolic network model. Bioinformatics 26: i255-i260
155. Yizhak K, Tuller T, Papp B, Ruppin E, (2011) Metabolic modeling of endosymbiont genome reduction on a temporal scale. Mol Syst Biol 7: 479
156. Yizhak K, Gabay O, Cohen H, Ruppin E, (2013) Model-based identification of drug targets that revert disrupted metabolism and its application to ageing. Nat Commun 4: 2632
157. Yizhak K, Gaude E, Le Dévédec S, Waldman YY, Stein GY, van de Water B, Frezza C, Ruppin E, (2014a) Phenotype-based cell-specific metabolic modeling reveals metabolic liabilities of cancer. eLife 3: doi: 10.7554/eLife.03641
158. Yizhak K, Le Dévédec SE, Rogkoti VM, Baenke F, de Boer VC, Frezza C, Schulze A, van de Water B, Ruppin E, (2014b) A computational study of the Warburg effect identifies metabolic targets inhibiting cancer migration. Mol Syst Biol 10: 744
159. Zamboni N, Sauer U, (2009) Novel biological insights through metabolomics and 13C-flux analysis. Curr Opin Microbiol 12: 553-558
160. Zomorrodi AR, Maranas CD, (2012) OptCom: a multi-level optimization framework for the metabolic modeling and analysis of microbial communities. PLoS Comput Biol 8: e1002363